Suppr超能文献

糖尿病可减轻瑞芬太尼预处理对缺血再灌注大鼠心脏的心肌保护作用,与生存的抗凋亡途径有关。

Diabetes mellitus mitigates cardioprotective effects of remifentanil preconditioning in ischemia-reperfused rat heart in association with anti-apoptotic pathways of survival.

机构信息

Department of Life Science, College of Natural Sciences, Ewha Womans University, Seoul, Republic of Korea.

出版信息

Eur J Pharmacol. 2010 Feb 25;628(1-3):132-9. doi: 10.1016/j.ejphar.2009.11.032. Epub 2009 Nov 26.

Abstract

Diabetes mellitus has been known to mitigate ischemic or pharmacologic preconditioning in ischemia-reperfusion injuries. Remifentanil is a widely used opioid in cardiac anesthesia that possesses a cardioprotective effect against ischemia-reperfusion. We evaluated whether diabetes affected remifentanil preconditioning induced cardioprotection in ischemia-reperfusion rat hearts in view of anti-apoptotic pathways of survival and Ca(2+) homeostasis. Streptozotocin-induced, diabetic rats and age-matched wild-type Sprague-Dawley rats were subjected to a left anterior descending coronary artery occlusion for 30min followed by 1h of reperfusion. Each diabetic and wild-type rat was randomly assigned to the sham, ischemia-reperfusion only, or remifentanil preconditioning group. Myocardial infarct size, activities of ERK1/2, Bcl2, Bax and cytochrome c, and gene expression influencing Ca(2+) homeostasis were assessed. Remifentanil preconditioning significantly reduced myocardial infarct size compared to ischemia-reperfusion only in wild-type rats but not in diabetic rats. Remifentanil preconditioning increased expression of ERK1/2 and anti-apoptotic protein Bcl-2 and decreased expression of pro-apoptotic proteins, Bax and cytochrome c, compared to ischemia-reperfusion only in wild-type rats. In diabetic rat hearts, however, remifentanil preconditioning failed to recover the phosphorylation state of ERK1/2 and to repress apoptotic signaling. In addition, diabetes minimized remifentanil induced modulation of abnormal changes in sarcoplasmic reticulum genes and proteins in ischemia-reperfusion rat hearts. In conclusion, diabetes mitigated remifentanil induced cardioprotection against ischemia-reperfusion, which might be associated with reduced recovery of the activities of proteins involved in anti-apoptotic pathways including ERK1/2 and the abnormal expression of sarcoplasmic reticulum genes as a result of ischemia-reperfusion in rat hearts.

摘要

糖尿病已知可减轻缺血或药物预处理引起的缺血再灌注损伤。瑞芬太尼是心脏麻醉中广泛使用的阿片类药物,具有抗缺血再灌注作用。我们评估了糖尿病是否会影响瑞芬太尼预处理对缺血再灌注大鼠心脏的保护作用,因为它涉及到生存和钙稳态的抗凋亡途径。链脲佐菌素诱导的糖尿病大鼠和年龄匹配的野生型 Sprague-Dawley 大鼠进行左前降支冠状动脉闭塞 30min,然后再灌注 1h。每个糖尿病大鼠和野生型大鼠都被随机分配到假手术、缺血再灌注或瑞芬太尼预处理组。评估心肌梗死面积、ERK1/2、Bcl2、Bax 和细胞色素 c 的活性以及影响钙稳态的基因表达。与仅缺血再灌注相比,瑞芬太尼预处理显著减少了野生型大鼠的心肌梗死面积,但对糖尿病大鼠没有影响。与仅缺血再灌注相比,瑞芬太尼预处理增加了 ERK1/2 和抗凋亡蛋白 Bcl-2 的表达,并降低了促凋亡蛋白 Bax 和细胞色素 c 的表达,野生型大鼠。然而,在糖尿病大鼠心脏中,瑞芬太尼预处理未能恢复 ERK1/2 的磷酸化状态并抑制凋亡信号。此外,糖尿病使瑞芬太尼诱导的缺血再灌注大鼠心脏肌浆网基因和蛋白质异常变化的调节最小化。总之,糖尿病减轻了瑞芬太尼对缺血再灌注的心脏保护作用,这可能与缺血再灌注后参与抗凋亡途径的蛋白质活性恢复减少以及肌浆网基因的异常表达有关。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验